天演药业上涨7.14%，报2.1美元/股，总市值9897.57万美元

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 7.14%, reaching $2.1 per share, with a total market capitalization of approximately $98.98 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, reflecting a year-on-year decrease of 99.43% [1] - The company's net profit attributable to shareholders was -$33.42 million, representing a year-on-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, aiming to discover and develop novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to create new antibodies with high safety and efficacy, benefiting cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]